Functionally, ATAD2 has been shown to act as a coactivator of various transcription factors including the androgen receptor (AR),4 and the proto-oncogene MYC,5 and studies examining gene silencing of ATAD2, using siRNA or shRNA, report it to have a role in tumour cell proliferation and survival.3,12 These studies suggest that ATAD2 is a potential target for cancer drug discovery, and small-molecule inhibitors would provide insight into the phenotypic response to the inhibition of ATAD2. The gene discussed is AR; the disease is neoplasm.